Cargando…

Health technology assessment: oncology drugs with orphan designation as an example

Detalles Bibliográficos
Autor principal:	Wild, Claudia
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958374/ http://dx.doi.org/10.1186/1750-1172-5-S1-O17

Ejemplares similares

Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010)

Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia
por: Yap, Christina, et al.
Publicado: (2011)

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
por: van den Brink, Rinke
Publicado: (2014)

Collaborative models for increasing efficiency of early drug assessment
por: Nachtnebel, Anna, et al.
Publicado: (2015)

Evidence synthesis in trial design: an example from the neurosciences
por: Egan, Kieren, et al.
Publicado: (2013)

How are systematic reviews used in the planning and design of health technology assessment funded trials?
por: Bhurke, Sheetal, et al.
Publicado: (2015)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Development of new in silico methods to identify ligands for orphan GPCR
por: Weill, Nathanael, et al.
Publicado: (2008)

OrphanAnesthesia – anesthesia recommendations for patients suffering from rare diseases
por: Münster, Tino
Publicado: (2014)

Role of animal models in oncology drug discovery
por: Kumar, R
Publicado: (2003)

Statistical issues in the design of randomised surgical trials: a practical example of the possible solutions
por: Marshall, Helen, et al.
Publicado: (2011)

Designing an information technology system in public health: observations from India
por: Thiagarajan, Sundararaman, et al.
Publicado: (2012)

OA02.06. Importance of drug authentication and standardization as per API with the example of Alpinia species
por: Nini, KG, et al.
Publicado: (2013)

Pro’s and con’s of the stepped wedge design in cluster randomised trials of quality improvement interventions: two current examples
por: Dreischulte, Tobias, et al.
Publicado: (2013)

Scope and management of Patient Registries for orphan rare disease (ORD) meeting the demands of all involved stakeholders
por: Hernberg-Ståhl, Elizabeth
Publicado: (2010)

Development of an evidence-based strategy to assess and manage substance use in oncology patients
por: Choflet, Amanda, et al.
Publicado: (2015)

Can we reduce bias in open-label trials when blinded outcome assessment is not possible? An example from the trigger trial
por: Kahan, Brennan, et al.
Publicado: (2015)

Targeting protein dynamics in drug design
por: Wade, Rebecca C
Publicado: (2013)

Assessing the relationship between contact sensitization and eczema in adolescents and adults on the example of nickel and neomycin: preliminary results of a meta-analysis of epidemiological data
por: Plichta, Danuta, et al.
Publicado: (2015)

On the validity of popular assumptions in computational drug design
por: Klebe, Gerhard
Publicado: (2011)

Adrenal masses in oncology patients
por: Reznek, Rodney H
Publicado: (2014)

Global challenges in oncologic imaging
por: Hricak, Hedvig
Publicado: (2014)

Treatment success in pragmatic randomised controlled trials: a review of trials funded by the UK Health Technology Assessment programme
por: Dent, Louise, et al.
Publicado: (2011)

Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
por: Schelleman, Hedi, et al.
Publicado: (2015)

Genetically modified cancer models: the value of luciferase-tagged tumors and in vivo luciferase-based reporter assays in oncology drug discovery
por: Yang, W, et al.
Publicado: (2003)

Application of next generation sequencing in oncology
por: Meyer, Brian
Publicado: (2014)

Development of novel oncology biomarkers for cancer
por: Yoganathan, Nathan
Publicado: (2014)

Incidental findings in the oncology patient: ovaries
por: Forstner, Rosemarie
Publicado: (2014)

Incidental lesion in oncology patients: kidneys
por: Sohaib, Aslam
Publicado: (2014)

Incidental findings in the oncology patient: liver
por: Schima, Wolfgang
Publicado: (2014)

Using the UK renal registry for a clinical trial in dialysis patients: the example of SIMPLIFIED
por: Bond, Simon, et al.
Publicado: (2015)

Pricing of orphan drugs in oncology and rare diseases
por: Nuijten, Mark, et al.
Publicado: (2020)

Health biotechnology development in Malaysia: targeting local and global health needs through health technology
por: Abuduxike, Gulifeiya
Publicado: (2014)

The “Podiatry Diabetes Model”- an example of an organised approach to the podiatric care of people with diabetes in regional Victoria
por: Perrin, Byron, et al.
Publicado: (2011)

Historical injustice in psychiatry with examples from Nazi Germany and others: ethical lessons for the modern professional
por: Strous, Rael
Publicado: (2007)

Methodological caveats in the environmental modelling and projections of climate niche for ticks, with examples for Ixodes ricinus (ixodidae)
por: Estrada-Peña, A
Publicado: (2014)

O072: A targeted MRSA surveillance in long-term-care facilities - Polish example
por: Wojkowska-Mach, J, et al.
Publicado: (2013)

Minimising oncological treatment of early breast cancer
por: Yarnold, J
Publicado: (2008)

Incidental findings in the oncology patient: pancreas and spleen
por: Gore, Richard M, et al.
Publicado: (2014)

A computational protocol to fragment-based drug design at PDB scale
por: Moriaud, F, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_e5i8v62ljttnuhn9k2gm2pdp7s